Check Claims Before You Publish

 Quick Explanation Copied

 Long Explanation

Citation Metrics and the Identity Problem

The supplied author-level citation record is unusable: it lists h-index 0, 2 papers, and 0 citations, and the two indexed works are Japanese-language control-theory papers — an obvious name-disambiguation artifact. In contrast, OpenAlex returns multiple "Xiaoping Liu" profiles, with the top candidates showing h-indices of 75 (25,750 citations, 701 works, ORCID 0000-0002-8703-6967, "Peter Xiaoping Liu") and 72 (19,356 citations, 703 works) OpenAlex disambiguated author profiles. Any fair review must therefore discard the zero-citation record and judge the author by the paper evidence itself. The reviewed papers (TeCD, HSM, pre-disease hallmarks, Plasmix) cluster around the Hangzhou Institute for Advanced Study/CAS Xiaoping Liu, a systems-biology and bioinformatics researcher — not the Ottawa cardiologist or Carleton control engineer.

Scientific Breadth and Methodological Strength

The sampled portfolio spans resource engineering, dynamic-network methods, and mechanistic cancer biology. The TeCD database standardized ~948,000 eccDNAs across five species (human, mouse, chicken, yeast, Arabidopsis) with BLAST-enabled retrieval and curated genome mappings TeCC eccDNA cross-species database. The Health State Manifold framework quantifies individual health via V (phenotypic state) and U (homeostatic resilience) scores across rat, mouse, and human multi-omics time series Health State Manifold multi-omics framework. The 2026 pre-disease hallmarks review synthesizes critical slowing down, bifurcation proximity, entropy, and dynamic network biomarkers into a generalizable Wei-Bing framework Pre-disease tipping-point hallmarks framework. Most impressively, the Plasmix proteomics study demonstrates that titration-gradient preservation — not technical CV — predicts cross-platform proteomic concordance (median correlation 0.624 vs 0.071), and that sample-to-reference anchoring lifts ICC≥0.50 from 0% to 88.1% of consensus proteins Plasmix cross-platform proteomics ruler.

Rigor, Limitations, and Blind Spots

Mechanistic work shows competent but conventional execution: the miR-101/METTL3 glioma study combines MeRIP-qPCR, RIP, and xenografts (n=5 mice/group) with public CGGA/TCGA survival analyses miR-101 METTL3 glioma autophagy axis, but in vivo samples are small and validation is cohort-correlative. The GBP2/SP1 pancreatic cancer study uses nine TCGA/GEO cohorts and a 90+90 tissue microarray with ubiquitination assays GBP2 SP1 pancreatic cancer mechanism, though direct causation of SP1 ubiquitination and adjusted prognostic independence remain unestablished. Earlier work includes WGCNA bladder-cancer biomarkers Bladder cancer WGCNA biomarkers and the TEP short-time-series causality method TEP short-time-series causality method. Key weaknesses across the portfolio: small in vivo sample sizes (n=3–5 per group in TREM2, miR-101, Plasmix validation constraints), reliance on retrospective public cohorts, missing external validation (radiomics MSI study), and low reproducibility scores for theoretical framework papers (pre-disease hallmarks: 4/10). Some sampled papers (Hepatozoon survey, wind-tunnel sand thresholds, UHT metamorphism) likely belong to different same-name authors — a disambiguation risk that itself reduces confidence in portfolio-level judgments.

Conclusion (moderate confidence): Judging only by paper-level evidence, this Xiaoping Liu is an established, methodologically innovative quantitative biomedical scientist whose strongest work (Plasmix, HSM, TeCD, pre-disease theory) creates reusable tools and concepts for the field, while weaker entries show typical early-to-mid-career rigor issues (small n, single-center designs, correlative-only validation). Identity ambiguity is the largest unresolved blind spot.

 BGPT Author Review

Scientific Quality

The OpenAlex profile (h-index 72-75, ~19,000-25,000 citations, 700+ works) indicates a highly established, productive researcher. Paper-level evidence shows strong methodological innovation (TeCD database, Health State Manifold, Plasmix titration benchmarking, TEP causality method) and willingness to build reusable resources with open data/code. However, the erroneous zero-citation record signals severe name-disambiguation problems that must be corrected. Mechanistic papers show moderate rigor: small in vivo groups (n=3-5), correlative-only cohort validation, and no external validation in several studies. The genuine novelty and resource-building of the strongest entries counterbalance conventional wet-lab work.

Communication Quality

Papers are generally well-structured with clear schematics, quantitative reporting, and deposited data (GSA, OMIX, Figshare, GitHub for Plasmix). The theoretical pre-disease framework paper, while conceptually rich, is dense and reproducibility scored only 4/10 due to absence of empirical datasets and open code. Some papers under-report sample sizes and statistical detail. Overall communication is solid but uneven between resource/mechanistic papers and theoretical ones.

Author Novelty

The portfolio shows genuine conceptual novelty: the pre-disease state hallmarks framework, health state manifold V/U decomposition, TEP short-time-series causality method, and the Plasmix titration ruler concept (novel insight that repeatability does not guarantee accuracy) are original contributions. However, many mechanistic cancer papers (GBP2, miR-101 axis, WGCNA biomarkers) follow well-trodden lncRNA/m6A/network-biology templates, tempering the overall novelty score.

Scientific Rigor

Strongest work (Plasmix, TeCD) is rigorous: benchmarking across platforms, deduplication protocols, bootstrap CIs, open code and data. Weaker entries show small sample sizes (n=3-5 mice/group), retrospective public-cohort dependence, missing external validation, no multiple-testing correction reporting, and single-cell-line designs (SKOV3, HA-VSMC). The theoretical framework paper lacks empirical grounding. Mixed rigor profile typical of a prolific applied methods-and-mechanism lab.